Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Non-Current Assets (2024 - 2025)

Xilio Therapeutics' Non-Current Assets history spans 2 years, with the latest figure at $9.6 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 15.37% year-over-year to $9.6 million; the TTM value through Sep 2025 reached $41.1 million, changed N/A, while the annual FY2024 figure was $10.8 million, N/A changed from the prior year.
  • Non-Current Assets for Q3 2025 was $9.6 million at Xilio Therapeutics, down from $10.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $13.4 million in Q1 2024 and bottomed at $9.6 million in Q3 2025.